VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: The IPO Pipeline's Quality Gap Is Widening Fast
Value Add VC/Pulse/IPO

The IPO Pipeline's Quality Gap Is Widening Fast

A $2.1 trillion IPO pipeline and 44.5% average first-day gains sit alongside Avalanche Treasury's 73% crash and underwater energy IPOs, showing 'golden age' framing masks diverging quality.

By the Numbers

$2.1T
IPO pipeline value
44.5%
Avg tech IPO 1st-day gain
-73%
AVAT stock decline
60%+
Energy IPOs underwater
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
July 23, 2026
2 min read
ShareXLinkedInEmail

THE RUNDOWN

1

Barclays has called 2026 a 'golden age' for tech IPOs, citing a $2.1 trillion cumulative pipeline valuation and technology IPOs averaging a 44.5% first-day gain, based on prior Value Add Pulse coverage of Barclays' and S&P Global's own published figures

2

That same week's news cycle features Avalanche Treasury crashing 73% since its June debut and warning it may not survive, alongside more than 60% of this year's energy-sector IPOs trading below their issue price despite a record $12.6 billion raised in H1 2026

3

Reformation's IPO filing -- strong revenue growth paired with declining profit -- and Starfighters Space's modest $17.5 million PIPE riding SpaceX's much larger halo effect both illustrate the same underlying pattern: capital is flowing readily into IPO-stage companies regardless of individual business quality

4

The gap between aggregate pipeline enthusiasm and individual-name aftermarket performance is the single most important thing for LPs and public-market investors to track heading into the back half of 2026's IPO wave

TC

The VC Read · Trace's Take

Trace Cohen

A $2.1 trillion pipeline and a 73%-crashed crypto-treasury stock warning it may not survive are both true at the same time this week, and that's the entire lesson -- aggregate IPO enthusiasm tells you about market capacity, not about which specific listing is going to work. Every founder and LP treating 'golden age of IPOs' as a green light for any listing needs to separate sector-level appetite from individual business quality, because this week just proved how far apart those two things can be.

Tech IPO Tracker →

Analysis

The aggregate IPO-market numbers this year genuinely support a 'golden age' framing: Barclays has pointed to a $2.1 trillion cumulative tech IPO pipeline valuation, and S&P Global has found technology IPOs averaging a 44.5% first-day gain in H1 2026 -- both figures well above historical norms for a healthy market. But this week's individual-name news cycle tells a sharply different story about what actually happens to these companies after the opening bell.

Avalanche Treasury, a Nasdaq-listed crypto-treasury vehicle, has crashed 73% since its June debut and is now warning it may not survive -- a collapse that happened well within the same 'golden age' window Barclays is describing. It's not an isolated case: more than 60% of this year's energy-sector IPOs are trading below their issue price despite a record $12.6 billion raised in H1 2026, meaning the pattern of strong IPO-stage fundraising followed by weak aftermarket performance extends across multiple sectors, not just one troubled name.

Even this week's more conventional listings show early signs of the same tension: Reformation's IPO filing pairs genuinely strong revenue growth -- 20 consecutive quarters of double-digit gains -- with declining net profit, a combination public investors will need to price carefully rather than simply reward on growth headline alone. Starfighters Space's modest $17.5 million PIPE riding the much larger SpaceX halo effect is a cleaner example still of capital flowing toward a sector label rather than purely toward individual business fundamentals.

“Diligence on individual business fundamentals, not sector-level enthusiasm, remains the only reliable way to tell those outcomes apart in advance.”

The throughline across all of these examples is the same: 2026's IPO market has genuine capacity and genuine investor enthusiasm in aggregate, but that enthusiasm is not yet reliably distinguishing between durable business models and speculative, narrative-driven listings before the capital gets deployed. Aggregate pipeline size and average first-day pop are measures of appetite, not measures of quality -- and this week's news is a clean illustration of how far apart those two things can be for any specific name.

For LPs and public-market investors, the practical takeaway is to treat every 'golden age of IPOs' headline as a description of market capacity, not a signal about any individual listing's durability -- the same aggregate conditions that let Reformation and three new SPACs file this week also let Avalanche Treasury raise capital before crashing 73%. Diligence on individual business fundamentals, not sector-level enthusiasm, remains the only reliable way to tell those outcomes apart in advance.

Watch for: whether Avalanche Treasury's collapse or the energy-IPO underperformance pattern causes any visible pullback in 2026's broader IPO pipeline enthusiasm; whether Reformation's aftermarket trading reflects investor concern about its declining profit; and whether Barclays or other banks adjust their 'golden age' framing if more high-profile IPO-stage names show this same aftermarket weakness in the coming months.

ShareXLinkedInEmail

More on

Avalanche Treasury Corp →

Reported by Value Add Pulse Analysis · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 9, 2026

What BofA's Extreme Bull Signal Means for Your Marks

Illustration for: What BofA's Extreme Bull Signal Means for Your Marks
IPO

What BofA's Extreme Bull Signal Means for Your Marks

BofA's Bull & Bear indicator hit 9.7, its highest since 2021 and above the firm's own 8.0 sell threshold — a trace's-take on what that extreme reading should change about how GPs mark portfolio companies against public comps.

IPO· Aug 8, 2026

Biotech IPOs Are Pricing Above Range Again

Illustration for: Biotech IPOs Are Pricing Above Range Again
IPO$532.5M combined

Biotech IPOs Are Pricing Above Range Again

BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.

IPO· Aug 7, 2026

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

Illustration for: BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq
IPO$150M IPO

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.

@Trace_Cohen·t@nyvp.com